Illumina, Inc. (ILMN) on Decifer

Decifer ranks ILMN number 13 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 12% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is expected to grow about 6% a year, profits grew 171% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• The single credible supplier of genomic sequencing in our worldview, still not widely recognized, with profits up 171% and momentum of 25 out of 35, an early name where low expectations meet a real role.

The current read

The evidence on ILMN lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Health: Illumina sits in the drug discovery layer of the GLP-1 & Metabolic Health story.

Read the full ILMN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.